OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
August 17, 2023
With this agreement, Chiesi Global Rare Diseases will co-develop drug delivery systems with Aliada Therapeutics for large-molecule therapeutics that can cross the blood-brain barrier.
A major grant from the Bill & Melinda Gates Foundation will bolster efforts to fight the global HIV/AIDS epidemic.
August 16, 2023
HitGen has entered into a research service agreement with Nested Therapeutics for use of HitGen’s DNA-encoded library for drug discovery.
August 11, 2023
Webinar Date/Time: Thu, Sep 28, 2023 11:00 AM EDT
August 03, 2023
The biggest hurdle is developing palatable formulations that are efficacious and patient friendly.
An intelligent drug development paradigm can enable small pharma to implement an effective early drug development approach.
August 02, 2023
mRNA may be a modality whose chief advances are yet to come.
August 01, 2023
In this episode, David Tisi and Reenal Gandhi provide expert insights into advances and innovations changing the drug dosage form landscape.
July 27, 2023
Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.